Efficacy and Safety of Roflumilast Foam 0.3% in Trial Participants With Seborrheic Dermatitis
This study will assess the safety and efficacy of Roflumilast foam 0.3% (ZORYVE®) versus vehicle applied once a day for 8 weeks by trial participants with seborrheic dermatitis.
Males and females ages 9 years and older (inclusive) at the time of consent. [+8]
Trial participants with any serious medical condition or clinically significant... [+26]